MedTrace Logo

Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

NCT04943588 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25000

Last updated 2025-03-24

No results posted yet for this study

Summary

We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.

Conditions

  • Hepatitis C, Chronic

Interventions

DIAGNOSTIC_TEST

HCV RNA (PCR)

We will test HCV positive patients after treatment to observe if they achieve SVR

DIAGNOSTIC_TEST

HCV Antibody test (Point of care)

HCV antibody test used to establish if patients have had or are actively infected with HCV

DIAGNOSTIC_TEST

AST/ALT and platelets measurement

AST/ALT and platelets to determine APRI score

Sponsors & Collaborators

  • Aga Khan University

    collaborator OTHER

  • Dow University of Health Sciences

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University of Bristol

    collaborator OTHER

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Graham R Foster, MBBS · Queen Mary University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2026-01-30
Completion
2026-01-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04943588 on ClinicalTrials.gov